The Social Chain AG

  • WKN: A1YC99
  • ISIN: DE000A1YC996
  • Land: Deutschland

Nachricht vom 22.06.2021 | 15:03

The Social Chain AG: The Social Chain AG is assessing options of an uplisting including a listing in the United States of America

The Social Chain AG / Key word(s): IPO
The Social Chain AG: The Social Chain AG is assessing options of an uplisting including a listing in the United States of America

22-Jun-2021 / 15:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Publication of an Insider Information pursuant to Article 17 MAR

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (COLLECTIVELY, "UNITED STATES") OR TO ANY U.S. PERSON (AS DEFINED BELOW), CANADA, AUSTRALIA OR JAPAN OR ANY OTHER COUNTRY IN WHICH SUCH PUBLICATION MAY BE UNLAWFUL OR IN WHICH THE OFFERING OF SECURITIES IS SUBJECT TO REGULATORY RESTRICTIONS. THERE ARE OTHER RESTRICTIONS. PLEASE SEE THE IMPORTANT NOTE AT THE END OF THIS PUBLICATION.

The Social Chain AG is assessing options of an uplisting including a listing in the United States of America


Berlin, 22 June 2021 - The Social Chain AG (Frankfurt Stock Exchange: PU11:Xetra, ISIN: DE000A1YC996) ("Company"), is currently evaluating the options of an uplisting of the shares currently listed on the Open Market of the Düsseldorf Stock Exchange ("Uplisting") including assessing a listing in the United States of America. It is currently intended to execute the public offering exclusively from new shares issued by The Social Chain AG as part of a capital increase from authorized capital. In preparation for the uplisting, the Management Board of the Company has resolved, with the consent of the Supervisory Board, to propose the adoption of a resolution for authorized capital to the Annual General Meeting of the Company.

The uplisting currently under consideration, including the option to list in the United States, is intended to support the Company to implement its expansion strategy.

The uplisting could be completed within the next 12 months, depending on market and other conditions. The terms of the offering, the timing of the transaction and the location of the listing will be decided by the Company at a later date.

The Social Chain AG: Social Commerce on a global scale

The Social Chain AG is reshaping the world of brands and commerce. Our strategy and our actions are "Digital first - direct to customer": from branding to marketing to direct sales of our products in the categories Food, Home & Living, Beauty, and Fitness. Our online shops are the most efficient points of sale for our Direct-to-Consumer brands. More than 70 percent of Direct-to-Consumer sales are performed by our owned and operated online shops. Our communities, with over 86 million followers worldwide, inspire our customers and amplify our brand messages. We manage the expansion of our Social Commerce system of communities, brands, digital points of sale and logistics via our integrated proprietary technology platform: LINKS which analyses interests, purchase intentions and product satisfaction along the entire digital customer journey. The Social Chain AG's headquarters are in Berlin, with additional locations in Munich, London, Manchester, New York, San Diego and Los Angeles.

Important note

This announcement constitutes neither an offer nor a solicitation to purchase or subscribe for securities of the Company.

This announcement is not intended for distribution, directly or indirectly, in or into the United States or within the United States and may not be distributed to U.S. persons (as such term is defined in Regulation S under the Securities Act) or publications with a general circulation in the United States. This announcement does not constitute or form part of any offer to sell or the solicitation of an offer to purchase or subscribe for any securities in the United States. The securities are not and will not be registered under the Securities Act and may not be offered or sold in the United States absent registration under the Securities Act or an exemption from registration under the Securities Act. The Company does not intend to conduct a public offering of securities in the United States.

The securities referred to in this announcement will not be offered or sold in Canada, Australia or Japan, or to or for the account of persons resident in Canada, Australia or Japan. No action has been taken to offer, acquire or distribute the securities in any jurisdiction where this is not permitted.

This release contains statements relating to the future. These statements are based on current views, expectations and assumptions of the Company's management and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied. Actual results, results or events could differ materially from those described herein due to factors affecting the Company, including, but not limited to, changes in the general economic environment or competitive situation, capital market risks, foreign exchange rate fluctuations and competition from other companies, and changes in foreign or domestic laws or regulations, including, but not limited to, the tax environment. The Company assumes no obligation to update any statements relating to the future.

Contact:
Jana Walker | Investor Relations
ir@socialchain.com


22-Jun-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021